Placeholder Banner

Trump Administration and Speaker Pelosi Surrender Powerful Tool for Reining in Foreign Free Riding

December 10, 2019
Media Contact
Author-Profile-Andrew-Segerman

Exclusion of biologics provisions in revised USMCA sets dangerous precedent for future trade talks,
including with China

Puts American jobs, intellectual property and leadership in medical innovation at risk

WASHINGTON – BIO President and CEO Jim Greenwood released the following statement in response to a renegotiated USMCA that excludes provisions that prohibit foreign countries and foreign companies from stealing American medical innovation:

“President Trump has promised to end foreign free-riding on American medical innovation, but by removing enhanced IP protections for biologic medicines, his administration just surrendered one of the most important tools that would help stop it.

“The Administration and Speaker Pelosi have missed a critical opportunity to raise intellectual property standards in key markets, create good American jobs and ensure that American biopharmaceutical companies have their ingenuity, innovation and hard work protected around the globe. They have forsaken a sector in which America leads the world, and which promises to be a key sector of our 21st century economy.

“Small U.S. biotechnology companies depend on their government to protect them in global markets and to ensure a level playing field.   

“Today’s announcement declares open season on these innovators and sends a clear message that the U.S. government will stand idly by while foreign entities attack American intellectual property, American jobs and America’s global leadership in medical innovation. 

“Foreign countries, including China, looking at this agreement will know that the U.S. government is not prepared to protect American innovation in the biopharmaceutical sector and that it can be pirated with impunity.

“The real losers today are America’s scientists, entrepreneurs and patients waiting for the next generation of breakthrough medicines.”

###

Discover More
Representatives John Joyce, M.D. (R-PA) and Wiley Nickel (D-NC) today introduced the Optimizing Research Progress Hope And New Cures (ORPHAN Cures Act). BIO President and CEO, Rachel King, made the following remarks: "This legislation is a welcome…
The Biden Administration today unveiled the first 10 prescription drugs that will be subject to price controls under the Inflation Reduction Act (IRA). Rachel King, BIO interim President and CEO, made the following statement: The Medicare price…
The Centers for Medicare & Medicaid Services (CMS) today released its guidance for the Drug Price Negotiation Program (Negotiation Program) under the Inflation Reduction Act of 2022 (IRA). John Murphy, BIO’s Chief Policy Officer, made the…